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The phosphatase and tensin homolog gene (PTEN ) on chromosome 10q23.3 is a nega-
tive regulator of the PIK3/Akt survival pathway and is the most frequently deleted tumor
suppressor gene in prostate cancer. Monoallelic loss of PTEN is present in up to 60% of
localized prostate cancers and complete loss of PTEN in prostate cancer is linked to metas-
tasis and androgen-independent progression. Studies on the genomic status of PTEN in
prostate cancer initially used a two-color fluorescence in situ hybridization (FISH) assay
for PTEN copy number detection in formalin fixed paraffin embedded tissue preparations.
More recently, a four-color FISH assay containing two additional control probes flanking the
PTEN locus with a lower false-positive rate was reported. Combined with the detection of
other critical genomic biomarkers for prostate cancer such as ERG, androgen receptor, and
MYC, the evaluation of PTEN genomic status has proven to be invaluable for patient strat-
ification and management. Although less frequent than allelic deletions, point mutations
in the gene and epigenetic silencing are also known to contribute to loss of PTEN func-
tion, and ultimately to prostate cancer initiation. Overall, it is clear that PTEN is a powerful
biomarker for prostate cancer. Used as a companion diagnostic for emerging therapeutic
drugs, FISH analysis of PTEN is promisingly moving human prostate cancer closer to more
effective cancer management and therapies.
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INTRODUCTION
Prostate cancer is one of the leading causes of cancer mortality in
men in the Western world. In the United States, it is the most com-
monly diagnosed cancer in men and second only to lung cancer
in the number of male cancer deaths (1). Prostate cancers display
a variable range of clinical behaviors, from slow-growing tumors
of little clinical significance to aggressively metastatic and lethal
diseases. Current prognostic tools, such as pre-operative prostate
specific antigen (PSA) levels, histological Gleason grading, clini-
cal tumor, node, and metastasis (TNM) staging are used to place
men in low-, intermediate-, and high-risk prostate cancer risk
groupings. However, these prognostic tools often fail to accurately
stratify individual patients at early stages of the disease. Although
<5% of patients exhibit advanced disease, up to 40% of patients
will eventually develop metastatic disease despite local therapy (2).
Localized cancers are usually treated with radical prostatectomy or
radiation. For more advanced cancers that have either recurred or
metastasized, the gold standard treatment is androgen ablation
therapy. Androgens play a central role in the normal development
and growth of the prostate gland as well as the abnormal growth
of prostate cancer. Androgen ablation by either surgical castration,
or luteinizing hormone-releasing hormone (LHRH) analog treat-
ments strongly inhibit the growth of localized advanced cancer
by eliminating circulating testosterone (3, 4). Although very effi-
cient at reducing cancer growth, this treatment eventually selects
for cells that are no longer responsive to such therapy, resulting
in a recurring lethal cancer within 18–24 months. This recurrent
cancer is often referred to as Castration Resistant Prostate Cancer
(CRPC) (5).
Given the broad spectrum of clinical and molecular behaviors,
the wide range of clinical outcomes and their associated treat-
ments, it is clear that prostate cancer is a highly heterogeneous
disease that presents great complexities in determining risk strati-
fication and appropriate treatment strategies. The main challenge
for physicians remains to distinguish indolent from clinically sig-
nificant tumors. With the goal of improving clinical management
of the disease, current efforts are focusing on identifying the genes
and understanding the pathways involved in mediating disease
progression and treatment resistance. A further short term goal of
genetic testing of tumor samples is the identification of appropri-
ate companion diagnostics, allowing stratification of patients for
treatment and monitoring of treatment.
GENETIC ALTERATIONS IN THE PI3K/Akt/mTOR SIGNALING
PATHWAY IN PROSTATE TUMORIGENESIS
One pathway with a prominent role in prostate cancer is the
phosphatidylinositide 3-kinases (PI3K) signaling pathway. Cur-
rent estimates suggest that this signaling pathway is up-regulated
in 30–50% of prostate cancers (6–8). PI3K signaling is initiated by
the activation of a number of receptor tyrosine kinases, includ-
ing platelet-derived growth factor receptor (PDGFR), insulin-
like growth factor receptor (IGFR), and epidermal growth factor
receptor (EGFR) (Figure 1).
Once activated, these receptors phosphorylate PI3K at the
cell membrane. Phosphorylated PI3K in turn phosphory-
lates phosphatidylinositol-4,5-diphosphate (PIP2), leading to the
accumulation of phosphatidylinositol-3,4,5-triphosphate (PIP3).
PIP3 recruits Akt (also known as protein kinase B) and
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FIGURE 1 |The PI3K/PTEN/Akt pathway. Binding of growth factors to
the receptor tyrosine kinase activates the receptor complex, which in turn
recruits and activates PI3K. Activated PI3K converts PIP2 to PIP3, which
subsequently mediates the phosphorylation of Akt through PDK1.
Phosphorylated Akt is active on a wide range of substrates, but one of its
most important targets is mTOR, which is involved in cell growth,
proliferation, and survival. Activated Akt also interacts with androgen
receptor (AR) in an androgen-independent manner, leading to
over-activation of the AR signaling pathway in castration resistant prostate
cancer. PTEN is a tumor suppressor that negatively regulates the pathway
by removing the 3-phosphate from PIP3, converting it back to PIP2. Loss
of PTEN leads to over-activation of Akt which, in turn, is associated with
uncontrolled cell proliferation, decreased apoptosis, and enhanced tumor
angiogenesis.
phosphoinositide dependent protein kinase 1 (PDK1) to the cell
membrane, where Akt is phosphorylated by PDK1. Phosphory-
lated Akt activity extends over a wide range of substrates, but
most importantly activates the mammalian target of rapamycin
(mTOR), which play a significant role in tumorigenesis (9). mTOR
is a serine/threonine kinase that plays critical roles in the regula-
tion of cell growth, survival, and division. Interaction between Akt
and androgen receptor (AR) can lead to AR activation in a ligand-
independent manner, ultimately up-regulating genes involved in
CRPC tumorigenesis (9).
The primary negative regulator of the PI3K pathway is the
tumor suppressor phosphatase and tensin homolog gene (PTEN ).
PTEN is a dual specificity protein and lipid phosphatase that
not only targets acidic residues in protein substrates, but more
importantly, the 3-phosphate from PIP3, converting it back to
PIP2 (10). PTEN signaling regulates cell division and can also
direct cells to enter a natural cell death pathway when suffi-
cient growth has taken place by inducing G1-phase cell cycle
arrest through the retinoblastoma protein (11, 12). As a regula-
tor of PI3K signaling, loss of PTEN leads to over-activation of
Akt, which, in turn, is associated with uncontrolled cell prolifera-
tion, decreased apoptosis, and enhanced tumor angiogenesis (13).
The PTEN tumor suppressor gene maps to human chromosome
10q23.3, and this region is known to exhibit high rates of loss
of heterozygosity in a variety of human malignancies, including
kidney, lung, breast, and prostate cancer (14). In prostate can-
cer, early reports on the PTEN gene focused on small changes
of DNA sequence or point mutations that led to inactivation
of PTEN protein function (15). In addition, the PTEN gene
may also be inactivated by epigenetic events such as promoter
methylation (16, 17). However in recent years, it has become
evident that relatively large deletions and genomic rearrange-
ments affecting PTEN are most prevalent in prostate cancer (8,
18). Mechanisms including transcriptional repression, microRNA
(miRNA) regulation (19), disruption of competitive endogenous
RNA (CeRNA) networks (20), and post translational modifica-
tions have also been implicated in the loss of PTEN function
and in the initiation of tumorigenesis (21, 22). However, this
review will mainly focus on PTEN alterations at the genomic
level.
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PTEN DELETION ANALYSES BY FISH
Fluorescence in situ hybridization (FISH) analyses have provided
a robust evaluation of the genomic status of PTEN in prostate
cancer. This assay design has a centromere probe as a chromo-
some copy number control, and the PTEN locus probe labeled
in a different fluorochrome. Using this FISH method, early stud-
ies by Yoshimoto et al. (23) analyzing 35 radical prostatectomy
specimens showed no PTEN deletion in benign glandular epithe-
lium or low-grade Prostatic Intra-epithelial Neoplasia (PIN), while
PTEN deletions were found in 23% of High-Grade Prostatic Intra-
epithelial Neoplasia (HGPIN), a pre-malignant stage of prostate
carcinoma, and 68% of overt prostate cancer. The authors con-
cluded that acquisition of a PTEN deletion is an important step
toward prostatic tumorigenesis (23). Subsequent studies have
demonstrated an association between PTEN loss and poor clini-
cal outcomes in cohorts ranging from 59 to 322 tumors samples,
confirming that PTEN alterations confer substantial malignant
potential to prostate cancer cells (24–26). Utilizing FISH to deter-
mine the hemizygous or homozygousPTEN deletion status,Yoshi-
moto et al. (8) analyzed paired primary adenocarcinomas and
regional lymph node metastasis derived from 10 patients and
determined that only 1 of the 10 patients retained both copies
of the PTEN locus in his matched pair biopsy. Hemizygous
PTEN deletion was found in both the primary and the metasta-
tic nodal tumor samples in 4 of 10 patients, while homozygous
PTEN deletion was found in both the primary tumor and their
metastatic lymph nodes in 3 of the 10 patients. Interestingly, 2
of the 10 patients with a hemizygous PTEN deletion in their pri-
mary adenocarcinomas, had positive lymph node biopsies that had
acquired a homozygous PTEN deletion (8). These findings sug-
gest that the transition from one-copy loss to two-copy loss may
be associated with metastasis (8). Subsequent supporting studies
demonstrated that hemizygous PTEN deletions were associated
with increased risk and earlier biochemical relapse after radi-
cal prostatectomy, whereas homozygous deletions were strongly
linked to metastasis and androgen-independent progression (24,
26, 27).
Despite being the method of choice for detecting genomic sta-
tus in FFPE sections, the reported frequency of PTEN deletion in
prostate cancer tissue using a two-color FISH assay varies widely.
To date, reports of PTEN deletions ranged from 20 to 60% of
localized prostate cancers (24–26). This large range in frequency
most likely results from a difference in tissue preparation, stage of
disease, and the methodology used to detect the aberration. Sev-
eral of the studies reported high cutoff values using the two-color
technology, and attributed this to artifacts generated during sec-
tioning. During tissue sectioning, part of the cell and nucleus can
be sliced out, leading to a “truncation effect” where loss of PTEN
signal from the nucleus could be scored falsely as gene deletion.
It is therefore essential that the false-positives likely to come from
truncation be determined by comparison with normal nuclei for
all deletion FISH assays (28). One solution for minimizing trun-
cation effects is the use of a four-color FISH assay incorporating
additional control loci. Recently, Yoshimoto et al. (29) reported
a meta-analysis of 311 published human genome array datasets
determined that the minimal prostate cancer-associated PTEN
deletion at 10q23.3 corresponds to a ∼2.06 Mb region flanked by
theBMPR1A and FAS genes. A four-color FISH assay was designed
to include BMPR1A and FAS probes flanking either side of the
minimal deleted region, a PTEN probe, and a chromosome 10
centromere copy control probe (29) (Figure 2).
In this four-color FISH assay design, loss of PTEN signal, but
presence of BMPR1A and FAS signals, indicates with a higher
degree of accuracy that a PTEN deletion is present rather than
a false-positive resulting from truncation effects. Loss of PTEN
signal along with loss of flanking probe signals could suggest
the presence of an artifact truncation loss. A recent comparison
study between a four-color PTEN FISH assay and a two-color
PTEN FISH assay using benign prostatic hyperplasia as a con-
trol tissue source for prostate cancer showed that two-color PTEN
FISH has a mean of 12% of false-positive cells due to truncation
losses whereas four-color PTEN FISH has a mean false-positive
rate of only 4%. Thus, the addition of these control flanking
probes provides three-dimensional information in FFPE sections
that increases specificity and sensitivity of the assay (29). Repre-
sentative deleted and normal PTEN FISH images are presented
(Figure 3).
Furthermore, using this four-color FISH assay, breakpoints
betweenPTEN andBMPR1A orFAS were mapped in 100 homozy-
gous and 82 homozygous PTEN losses. The results revealed that
69% of the samples had one breakpoint within the 940-kb interval
between BMPR1A and PTEN, suggesting that this interval was a
“breakpoint cluster hotspot” (Figure 4).
This region appeared to coincide with segmental duplica-
tion sites SD17 and SD18, containing at least 13 homologous
inverted repeat sequences over 10 kb in length, which could pro-
mote intrachromosomal mis-pairing during homologous DNA
repair or DNA replication. This genomic instability is the most
likely mechanism by which PTEN deletion is mediated in prostate
cancer (29).
FIGURE 2 | Schematic depiction of chromosome 10 showing the probe
locations of the PTEN four-color FISH assay; based onYoshimoto et al.
(29). The four-color FISH assay was designed to include BMPR1A (green) and
FAS (aqua) probes flanking either side of the 2.06-Mb minimal deleted region,
a PTEN probe (orange) at 10q23.3 and a chromosome 10 centromere (red)
copy control probe.
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PTEN DELETIONS DETECTED IN CIRCULATING TUMOR CELLS
Circulating prostate tumor cells are cells that have broken free
from the tumor and circulate in the peripheral circulation. Most of
these circulating tumor cells (CTCs) that depart from the primary
tumor will die, whereas an estimated 0.01% of CTCs are likely
to give rise to metastases (30). Despite having important prog-
nostic and therapeutic implications, CTCs have not been widely
studied in prostate cancer because of the technical challenges of
their detection. Early studies have shown that PSA-positive CTCs
from the peripheral blood of patients suffering from multifo-
cal cancers could be subjected to genetic profiling along with
tissue isolated from each cancer focus by multiplex PCR-based
microsatellite analysis (31–33). Results showed that the muta-
tions detected in CTCs were most likely derived from only one
distinct focus, while other foci from the same tumor sometimes
had additional LOH. Interestingly, the highest LOH in the PSA-
positive CTCs was observed at the PTEN locus, suggesting that
PTEN genetic imbalances might be associated with the occurrence
of CTCs in the peripheral blood of patients and with early bio-
chemical recurrence (33). An additional study using FISH analysis
of PTEN showed heterogeneous loss of PTEN in prostate can-
cer CTCs (34). Their data demonstrated that 6 of 13 patients
had homogenous homozygous loss of PTEN in all their CTCs,
while 7 patients had heterogeneous PTEN loss with combinations
FIGURE 3 | Phosphatase and tensin homolog gene four-color FISH
assay. (A) Normal, non-deleted tissue with red signals showing
chromosome 10 centromere regions, green signals showing the presence
of BMPR1, blue signal showing the presence of FAS, and yellow signal
indicating the presence of the PTEN gene; and (B) deleted PTEN locus, the
yellow signals corresponding to the PTEN gene are absent indicating
homozygous deletion of PTEN.
ranging from a mixture of heterozygous loss/normal PTEN to
heterozygous/homozygous PTEN loss (34). With emerging tech-
nology such as the CellSearch detection method, isolation of CTCs
from the peripheral blood of patients is now becoming a valid alter-
native source of tumor tissue that can be subjected to molecular
characterization, FISH analyses, and cancer monitoring (35).
PTEN DELETIONS AND ASSOCIATED BIOMARKERS IN
PROSTATE CANCER
The importance of PTEN genomic status for prostate cancer prog-
nosis is compelling but understanding its co-operation with other
genetic aberrations in the context of this highly heterogeneous
disease is crucial for accurately predicting clinical outcomes and
developing targeted therapies. One of the most pivotal interac-
tions in both human and murine prostate cancer is that between
PTEN and the ETS-related gene, ERG. Genomic alterations of
ERG resulting from a fusion with the androgen responsive trans-
membrane protease, serine 2 (TMPRSS2) gene are highly pervasive
in prostate cancer and can be detected in about 40–70% of clin-
ically significant diseases. Several studies have confirmed that
tumors with TMPRSS2:ERG gene rearrangements are enriched
for PTEN genomic deletions in localized prostate cancer and
CRPC (18, 24, 25, 36). Bismar et al. (37) reported that these two
genetic alterations showed significant concurrence within the same
tumor focus, ranging between 44 and 71% of hemizygous and
homozygous PTEN deletions, respectively. King et al. (38) and
Carver et al. (39), confirmed this association in a murine model,
both documenting that the development of invasive prostate can-
cer in double-transgenic models occurs at a higher rate than in
ERG rearrangements or PTEN genomic deletions alone. Further-
more, Bismar et al. (24) proposed that the synergistic co-operation
between PTEN deletion and ERG rearrangement could be a sig-
nificant driver for PCA development and tumor progression. A
subset of PCA may be driven initially by PTEN genomic instabil-
ity, which may facilitate the chromosomal rearrangement leading
to gene fusion formation and progression of cancer. Subsequent
PTEN deregulation by homozygous deletion could then occur to
induce invasive PCA possibly through Akt activation (Figure 5). In
a recent study using a Tissue MicroArray (TMA), Krohn et al. (40)
analyzed PTEN status in 2217 hormone naive and 49 hormone-
refractory tumors. Their data showed that PTEN deletion was
strongly associated with ERG fusion-positive tumors (29.1 versus
10.7%), suggesting a selective advantage for tumor cells harbor-
ing both PTEN deletion and ERG fusion (40). However, their
FIGURE 4 | Map of the breakpoint cluster region between BMPR1 and
PTEN . The 940-kb interval between BMPR1 and PTEN includes the
segmental duplication clusters SD17 and SD18, which are 35 kb and 379 kb in
length, respectively. Both contain clusters of homologous inverted repeat
sequences thought to cause genomic instability and mediate PTEN deletion.
Based on Yoshimoto et al. (29).
Frontiers in Oncology | Molecular and Cellular Oncology September 2013 | Volume 3 | Article 240 | 4
Phin et al. PTEN genomic rearrangements in prostate cancer
FIGURE 5 | Model for possible sequence of genomic events in PCA
progression. The acquisition of PTEN haplo-insufficiency in prostatic
precursor results in a decrease in PTEN protein level, which could lead to
genomic instability and the formation of high-grade prostatic intra-epithelial
neoplasia (HGPIN). This genomic instability could facilitate ERG
rearrangement, and together, synergistic co-operation between PTEN and
ERG abnormalities is associated with early steps of PCA formation.
Continuing genetic instability generates “PTEN null” subclones and allows
the selective advantage for further tumor progression through activation of
the Akt pathway. Modified from (24).
findings also suggested that ERG fusion is not required for PTEN
loss to determine aggressive tumor behavior, because PTEN dele-
tion in both ERG fusion-positive and fusion-negative cancers was
independently linked to poor prognosis, while the presence of
ERG fusion was unrelated to patient prognosis (40). Collectively,
these FISH studies of PTEN gene loss and ERG gene rearrange-
ments could be pursued for patient stratification and patient
management.
The AR is a steroid receptor member of the larger nuclear
receptor superfamily, and plays a central role in normal prostate
development as well as in prostate cancer initiation and progres-
sion. Androgen deprivation is currently the standard therapy for
metastatic prostate cancer, but patients invariably relapse with a
more aggressive CRPC. It has been widely recognized that AR sig-
naling remains important even in the presence of reduced andro-
gen levels and thus remains a major target for targeted therapeutic
interventions. In 43 primary prostate cancer samples, Choucair
et al. (41) determined that AR expression was significantly lower
in prostate cancer tumors harboring a PTEN deletion compared
to those with no PTEN deletion. However, the underlying mecha-
nism associating decreased AR expression in the presence of PTEN
deletion is still unclear (41). El Sheikh et al. (42) also showed in 47
samples of hormone naive prostate cancers that reduced expres-
sion of either biomarker was associated with the development of
androgen independence and reduced survival in patients whose
tumors remained androgen dependent (42). In contrast, Sircar et
al. (26) reported a positive correlation betweenPTEN deletion sta-
tus and up-regulation of AR expression in CRPC patients. These
results suggest that AR expression levels differ according to the
stage of the disease, with genomic amplification of AR likely to
occur in CRPC, but rarely in untreated prostate cancer (43, 44).
Therefore,AR gene amplification may play a direct role in prostate
cancer progression and may be associated with failure of androgen
deprivation therapy (ADT). Since AR expression levels are low in
hormone naive tumors, addition of an inhibitor of PI3K/mTOR
to the standard ADT of advanced prostate cancer may therefore
be beneficial to patients with PTEN deleted tumor. A number
of other studies have implicated differential expression of AR and
PTEN deletions/Akt activation as significant predictors for disease
progression and the development of CRPC (37, 44, 45). Their data
suggest that assessment of PTEN /AR co-expression proves useful
in distinguishing prostate cancer with a more favorable prognosis
from those with a high likelihood of developing recurrent disease.
The proto-oncogene MYC has been associated with cell trans-
formation. It is known that overexpression of MYC can immor-
talize human prostatic epithelial cells, so gain of function of MYC
is clearly an oncogenic factor in human prostate cancer. Com-
parative Genomic Hybridization (CGH) studies have showed that
gain of 8q, including 8q24 involving the MYC gene, is one of the
most frequent alterations in prostate cancer (46). In a compre-
hensive study using FISH with probes for MYC (8q24),∼40% of
primary tumors and>90% of metastases showed varying levels of
MYC copy number gains (47). Whereas primary tumors typically
have simple gain of MYC due to an extra copy of 8q, metastases
have more frequent regional MYC amplification, suggesting that
MYC is more commonly involved in prostate cancer progression
(15). Recently, Zafarana et al. (48) reported for the first time the
combined role of PTEN loss and MYC gain using global high-
resolution CGH analyses validated by FISH in a cohort of 126
intermediate-risk prostate cancer patients after receiving radio-
therapy. They reported that copy number alterations in PTEN
(allelic loss) and MYC (allelic gain) were associated with sig-
nificantly increased genetic instability and biochemical relapse
compared to tumors with normal PTEN and MYC status. In light
of these results, triaging patients by the use of PTEN and MYC
copy number changes within pre-treatment biopsies may allow for
better use of systemic therapies to target sub-clinical metastases or
locally recurrent disease and improve clinical outcomes (48).
PTEN MUTATION AND METHYLATION ANALYSIS
In addition to allelic deletion, functional loss of PTEN can also
be caused by mutations and epigenetic modifications. Some of
the most frequent mutations identified in PTEN are frameshift
or non-sense mutations that lead to inactivation of the protein
(Table 1). In localized prostate cancer, the incidence of PTEN
mutations has been found to occur at <20%, a frequency notably
lower than that of PTEN deletions (∼40% of localized cancers)
(2, 49–53). However, in advanced and metastatic disease, PTEN
appears to be more frequently mutated in up to 60% of patients
who had multiple metastases as well as in cell lines and xenografts
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Table 1 | Mutations in the PTEN gene identified in prostate cancer.
Exon Position Predicted effect Reference
Exon 1 G20STOP Non-sense Dong et al. (55)
Exon 2 R55G Missense Dong et al. (55)
Exon 3 T38G Inactivation Krohn et al. (40)
Exon 5 E91Q Inactivation Suzuki et al. (7)
R387STOP Non-sense Suzuki et al. (7)
H118Y Inactivation Krohn et al. (40)
I101A Missense Dong et al. (55)
I135V Missense Dong et al. (55)
Q150G Missense Dong et al. (55)
Q110STOP Non-sense Dong et al. (55)
P95S Missense de Muga et al. (63)
A164STOP Non-sense de Muga et al. (63)
Exon 6 564 Non-sense Cairns et al. (49)
Exon 7 c.761–765del Frameshift Cairns et al. (49)
c.672–673Ins Non-sense Suzuki et al. (7)
c.224Ins Frameshift Suzuki et al. (7)
D223N Missense de Muga et al. (63)
Exon 8 E201STOP Non-sense Krohn et al. (40)
D326N Inactivation Krohn et al. (40)
H272Y Missense Dong et al. (55)
Exon 9 T348I Missense Dong et al. (55)
K344R Missense Dong et al. (55)
T382S Missense Dong et al. (55)
derived from metastatic prostate cancer (7, 54). PTEN appears
to be more frequently mutated in metastases of prostate cancer,
providing further evidence for the idea that PTEN plays a crucial
role in the progression of prostate cancer (55). Recent advances
in massively parallel DNA sequencing technologies, allowing for
the identification of base substitutions as well as indels and copy
number alterations at greater sensitivity and cost effectiveness than
screening by traditional Sanger sequencing, have great promises to
offer a new strategy for personalized cancer care. Several studies
have shown that targeted mutational and copy number analy-
ses in advance prostate cancer using Next-Generation Sequencing
(NGS) were able to detect PTEN somatic point mutations as well as
genomic deletion in up to 44% of analyzed patient samples (2, 56,
57). The comprehensive genomic profiling that NGS technologies
offer is an exciting new tool that will not only help in the discovery
of new biomarkers but also in the design of personalized ther-
apies in the context of such a heterogeneous disease. Epigenetic
inactivation of the PTEN promoter has been identified in mul-
tiple types of cancers such as thyroid, lung, cervical, and breast
cancer (58). Even though several genes such as APC, GSTP1, and
MGMT, are known to be highly methylated in prostate cancer
(59–61), to date, limited data has shown the occurrence of PTEN
methylation in prostate cancer. One study using prostate cancer
xenografts, demonstrated by Northern analysis and RT-PCR that
the level of PTEN mRNA expression was reduced or absent in five
of the nine xenografts studied. The mRNA expression was then
restored with the demethylating agent 5-azadeoxycytidine in at
least one of the five xenografts suggesting that methylation of CpG
islands in the PTEN genomic locus was responsible for decreased
PTEN expression. However, it is also possible that the effect of
5-azadeoxycytidine on PTEN is mediated indirectly through a sec-
ond gene, such as a transcription factor that may be the true target
of methylation. Direct evidence that the PTEN gene is methylated
in prostate cancer is still required (17, 62).
EMERGING ANTICANCER THERAPIES FOR PTEN-DEFICIENT
PROSTATE CANCERS
Because PTEN is a tumor suppressor that negatively regulates the
PI3K pathway, up-regulation of this pathway’s downstream tar-
gets is commonly observed in PTEN-deficient prostate cancers.
Both Akt and mTOR are two important PI3K targets that are fre-
quently activated in human primary prostate cancer specimens, as
evidenced by increased phosphorylation of both Akt and S6RP, a
downstream target of mTOR (64, 65). The development of spe-
cific inhibitors for either one of these kinases has thus emerged
as important cancer therapeutic targets. It was reported that inhi-
bition of mTOR by rapamycin analogs such as ridaforolimus or
temsirolimus showed antitumor effects in clinical studies (65–68).
MK-2206 has also recently emerged as a potent allosteric inhibitor
of Akt and is currently in Phase 1 trial studies for the treatment
of prostate cancer (69). Recently, Zhang et al. (70) showed that
inhibition of either mTOR with ridaforolimus or Akt with MK-
2206 alone had no effect on the status of the other kinase in
castrate-sensitive settings. However, simultaneous inhibition of
both mTOR and Akt demonstrated additive antitumor effects (70).
These findings strongly indicate that the mTOR signaling network
in the PTEN-null tumor is independent of Akt activity and that
both Akt and mTOR downstream signaling pathways play a part
in PTEN-deficient prostate tumors. These results strongly support
the rationale for using Akt and mTOR inhibitors in combination
therapy (ClinicalTrials.gov identifier NCT01295632).
Most recently, the mTOR inhibitor drug Everolimus was eval-
uated in a Phase 2 trial as a first-line treatment in patients
with mCRPC (ClinicalTrials.gov identifier NCT00976755) (71).
Everolimus has been reported to inhibit tumor growth in human
prostate cancer cell lines as well as in transgenic mice expressing
human Akt (72). Everolimus treatment was also shown to increase
sensitivity to mTOR inhibition in tumors cells with PTEN loss
in vitro (73, 74). In this study 35% of chemotherapy-naïve patients
with mCRPC treated with a daily dose of 10 mg of single-agent
Everolimus showed progression-free survival (PFS) at the primary
end point of 12 weeks. Thirty percent of analyzable tumor sam-
ples were found to have a PTEN deletion determined using FISH,
and those in particular showed a trend toward longer PFS after
treatment. Despite modest activity in some patients with mCRPC,
Everolimus is a promising candidate drug for treating PTEN-
deleted prostate tumors, and further investigations of this drug
in combination with other therapies are warranted.
Targeting AR through androgen ablation therapy is the main-
stay of prostate cancer treatment. However, these cancers often
progress and, as a result, treatment options become limited. While
often termed“androgen-independent,”recent work has shown that
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AR signaling remains critical throughout the course of the disease
(75). This hypothesis has been validated by the clinical successes
of a new generation of potent AR antagonists such as MDV3100
or antiandrogen agents such as bicalutamide and abiraterone (76,
77). Recently, it has also been demonstrated that the AR and PI3K
signaling pathways are feedback regulated in a reciprocal man-
ner (78). That is, androgen independence, commonly associated
with PTEN loss, is associated with the activation of PI3K signal-
ing; conversely, PI3K inhibitors can reactivate androgen signaling
and sensitivity to antiandrogen therapy. In particular, recent stud-
ies have identified several mechanisms for the crosstalk between
AR by mTOR (79–81). In light of these findings, Squillace et al.
(82) recently demonstrated that dual inhibition of AR and mTOR
with bicalutamide and ridaforolimus, respectively, had synergis-
tic antiproliferative effect in prostate cancer cells in vitro when
compared with each agent alone (82).
The combination therapy resulted in full inhibition of each
pathway and exhibited potent antitumor activity with paral-
lel reductions in plasma PSA levels in xenograft models. Taken
together, ridaforolimus and bicalutamide represent a potentially
effective combination strategy for PTEN-deficient prostate cancer
therapy. Considering the success of these new compounds and
their mechanisms of action, the identification of PTEN deletions
has the potential to be a useful companion diagnostic assay for
therapeutics targeting the PIK3/mTOR pathway.
CONCLUSION
Over the past decade, extensive research has led to a more detailed
understanding of the molecular mechanism(s) governing the ini-
tiation and progression of prostate cancer. Although significant
progress has been made in our ability to forecast outcomes for
prostate cancer after therapy using clinical and histological vari-
ables, the ability to accurately predict response to a specific treat-
ment remains elusive. Molecular and cytogenetic assays such as
FISH analyses of PTEN have paved the way to a much clearer
understanding of cancer status and disease progression. With the
improved design of the four-color FISH assay, PTEN genomic
status can be used as a reliable diagnostic tool and potential
companion diagnostic for emerging anticancer drugs. Overall it
is clear that the status of PTEN is a powerful biomarker that
promise effective diagnosis and improved patient stratification and
management.
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